ERBB2 and breast carcinoma: Research from recent clinical trials has demonstrated positive effects of HER2-specific vaccinations that, when paired with chemo-drugs, could synergistically inhibit the recurrence of breast cancer, creating robust immunity and sustaining elevated CTL rates.